MDR1基因多态性与乳腺癌化疗疗效及血液毒性关系的研究

目的:探讨MDR1基因多态性与乳腺癌患者化疗疗效以及血液毒副反应的关系。方法:筛选70例新辅助化疗的女性患者,利用PCR-RFLP技术检测其外周血MDR1C3435T基因型,分析不同基因型患者化疗后的疗效及血液毒副反应。结果:70例新辅助化疗患者当中,3435TT基因型化疗有效率仅为23.1%,与3435CC和3435CT基因型相比差异有统计学意义(χ2=6.122,P=0.047,95%CI:0.043～0.051);血液毒性方面,3435CC型患者中性粒细胞Ⅲ～Ⅳ度减少的发生率为6.7%,较CT型(37.5%)和TT型(53.8%)发生率低(χ2=7.512,P=0.023,95%CI:0.016～0.021)。结论:携带MDR1 3435C等位基因的患者其化疗疗效可能较好;携带3435T等位基因的患者其中性粒细胞减少的风险可能较高。

MDR1 polymorphism predict response and hematologic toxicities in breast cancer patients treated with preoperative chemotherapy

OBJECTIVE: To investigate whether MDR1 polymorphisms are associated with therapeutic outcome and hematologic toxicities of preoperative chemotherapy in breast cancer patients.METHODS: MDR1 variants were determined in the blood samples from 70 patients by using PCR-RFLP technique.An analysis was carried out among the genotypes and therapeutic outcome and hematologic toxicities.RESULTS: The efficient rate of patients carrying MDR1 3435TT was 23.1%,significantly lower than those carrying CC or CT(χ2=6.122,P=0.047,95%CI:0.043-0.051).Patients carrying MDR1 3435CC showed a significantly lower toxicity response rate of Ⅲ-Ⅳ degree neutropenia(6.7%) than those with 3435 CT(37.5%),3435TT(53.8%,χ2=7.512,P=0.023,95%CI:0.016-0.021).CONCLUSION: Patients carrying MDR1 3435C allele may have better response to chemotherapy,and those with T allele may have an increased risk of developing neutropenia.